Board summary
Key figures
40,576
Registered population
59.8% aged 18–64
16.2%
Aged 65+
ICB 14.9% · England 17.9%
20.1%
Ethnic minority (non-White)
9.5% Asian · England 9.6%
13.3%
In IMD quintile 1
ICB 40.7% · England 21.0%
~5,034
Core20 residents (est.)
Resident basis; registered basis ~5,111 · see page 3
5,360
Hypertension register
+6.35% in 3 yrs · England +5.60%
489
SMI register
19.6% of Bury (LAD)'s
565
COPD register
Reviews -3.16% in 3 yrs
Forecast to 2030
6,127
Hypertension patients, 2030
+767 on today
67.4%
QRISK ≥20% on statins, 2030
+2.79pp over 3 yrs
3.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure and COPD reviews fell over 2023-2025.
Over 2023 to 2025, heart failure reviews fell 5.0% (England +8.7%) and COPD reviews fell 3.2% to 73.1% (England +2.8%, 76.4%), suggesting recall gaps.
High-risk lipid therapy trails ICB and England.
Lipid-lowering therapy for QRISK ≥ 20% is 61.4%, below Bury (LAD) (64.2%), NHS Greater Manchester Integrated Care Board (67.0%) and England (63.6%).
Three-year SMI physical health checks outpaced England.
Over 2023 to 2025, SMI BMI recording rose +12.2 pp to 82.4% (England +5.1 pp) and blood pressure checks rose +10.7 pp to 83.4%.
Population, age and ethnicity
Prestwich serves a younger registered population alongside high severe mental illness prevalence
Prestwich PCN registers 40,576 patients. The network is younger than average: 24.0% (9,753 patients) are aged 0-17, compared with 21.1% in Bury (LAD), 21.8% in NHS Greater Manchester Integrated Care Board and 19.6% in England. Patients aged 65+ comprise 16.2% (6,579 patients; England 17.9%, Bury (LAD) 17.6%, ICB 14.9%). Census usual-resident estimates indicate 20.1% are from ethnic minority groups, including 9.5% Asian / Asian British (England 9.6%, Bury (LAD) 10.6%, ICB 13.6%) and 4.5% Other ethnic group (England 2.2%, Bury (LAD) 1.9%, ICB 2.3%). Population growth to 2030 is projected at 0.8% with unverified methodology.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bury (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bury LA) | 2,139 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bury LA) | 1,051 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bury LA) | 21.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Overall PCN Core20 deprivation is 13.3% and concentrates sharply across member practices
Prestwich PCN's Core20 share is 13.3%, below Bury (LAD) at 27.9%, NHS Greater Manchester Integrated Care Board at 40.7%, and England at 21.0%. Average IMD decile is 5.0. Weighted practice Core20 share is 12.60% (a 0.67 percentage point discrepancy). Deprivation concentrates at St Gabriel's Medical Centre (28.99% share; 2,544 estimated patients), while Fairfax Group Practice accounts for the largest volume (8.22% share; 1,167 estimated patients). Preventive capacity should balance intensive outreach at St Gabriel's Medical Centre with scalable interventions at Fairfax Group Practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
489
SMI register
1.18% recorded prevalence
235
Learning disability register
0.57% recorded prevalence
21
Care homes, 773 beds
In the PCN catchment
9.4%
Provide unpaid care
Bury (LAD), Census 2021
The PCN records 489 patients with severe mental illness (1.2% prevalence, compared with 1.2% in Bury (LAD), 1.1% in NHS Greater Manchester Integrated Care Board and 1.0% in England) and 235 on the learning disability register (0.6% across all comparators). The catchment also contains 21 care homes with 773 beds. Higher severe mental illness prevalence than England and substantial care-home capacity require sustained proactive review workloads.
Severe mental illness: physical health checks
Recorded severe mental illness prevalence is 1.2% (England 1.0%). Annual physical checks reached 83.4% for blood pressure (England 83.4%) and 82.4% for BMI (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,360
Hypertension register
+6.35%
Register growth, 3 yrs
Bury (LAD) +6.10% · England +5.60%
+4.48pp
BP control, under 80
≤140/90 · +5.23pp aged 80+
+767
More patients by 2030
Forecast 6,127 (14.67%)
Hypertension case-finding and control
Hypertension QOF prevalence is 13.0% (5,360 patients), below Bury (LAD) (15.2%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%), indicating a modelled crude gap of +794 to +820 patients that is not age-adjusted. Over 2023 to 2025, prevalence grew +6.3% (England +5.6%). Process delivery is stable: 89.7% of hypertensive patients had a recent blood pressure check (Bury (LAD) 88.8%, England 90.0%), and 70.6% were treated to target, exceeding England (70.3%) and matching Bury (LAD) (70.7%). Lower crude prevalence alongside strong treatment control suggests opportunistically checking unrecorded blood pressure readings could identify missing diagnoses.
Lipids and statins
At 61.4%, lipid-lowering therapy for patients with QRISK ≥ 20% trails England (63.6%), Bury (LAD) (64.2%) and NHS Greater Manchester Integrated Care Board (67.0%). In 2026, lipid-regulating prescribing reached 1,557 items per 1,000 adults aged 18 and over, below England (4,100 rate), Bury (LAD) (2,245 rate) and the ICB (2,298 rate).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 48,000 | £2.20 | £1.94 | £1.86 | £105,600 |
| Cardiovascular (all), 2025 | 67,421 | £3.48 | £3.15 | £3.33 | £234,625 |
In 2026, the PCN prescribed 48,000 lipid-regulating items at £2.20 per item (England £1.86, Bury (LAD) £1.91, NHS Greater Manchester Integrated Care Board £1.94), spending £16,320 more than at England's unit cost across 48,000 items. Unit cost differences provide context for local formulary and prescribing reviews.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.70%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.94%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.4% (565 patients), below Bury (LAD) (2.1%) and England (1.9%), having fallen -1.7% over 2023 to 2025 (England +2.6%). Annual COPD reviews fell -3.2% to 73.1% (England +2.8% to 76.4%, Bury (LAD) 77.8%). Asthma prevalence is 6.4% (2,456 patients; England 6.6%), with 12-month reviews at 64.1% (England 65.7%), leaving about 880 patients without a recorded review.
Cancer register and children's immunisation
Cancer prevalence is 3.3% (1,367 patients vs 3.8% in England). In Q1 2025/26 childhood immunisations, age-5 MMR dose 1 reached 95.5% (England 91.7%), exceeding the 95.0% target. However, MMR dose 2 fell to 91.0% (a 4.5 pp dose difference) and the 4-in-1 booster reached 88.3%, trailing the 95.0% target by 6.7 pp. Pre-school booster attrition leaves an under-protected cohort requiring coordinated practice recall before primary school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, NHS Greater Manchester ICB recorded 55.6% of known-stage cancers diagnosed at stage 1 or 2 (6,491 of 11,679), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of registrations (11,679 of 16,492). Across Prestwich PCN, cervical screening reached 71.7% (England 66.8%), but practice coverage was 59.1% at St Gabriel's Medical Centre and 64.6% at Greyland Medical Centre. Uneven screening uptake leaves underserved cohorts at greater risk of late presentation.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Manchester University NHS Foundation Trust achieved 72.8% on the 62-day cancer standard, 12.2 pp below the 85.0% standard, compared with 78.6% at Northern Care Alliance NHS Foundation Trust, 69.7% at Bolton NHS Foundation Trust, 75.7% across NHS Greater Manchester ICB, and 71.2% nationally. The 28-day faster diagnosis standard reached 80.1% (Northern Care Alliance 75.2%, England 79.3%). Diagnostic 6-week waits at Manchester University NHS Foundation Trust were 11.7% for MRI and 13.0% for cystoscopy (Northern Care Alliance 0.0%). Treatment delays at acute providers could prolong diagnostic intervals for referred PCN patients.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Bolton | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 80.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.50 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 69.66 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Bolton | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 2.05 | 21.40 |
| CT | 14.66 | 4.10 | 19.40 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 3.48 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.33 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 2.06 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 15.78 | 23.14 |
| Community services activity | Bury residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 58,875 | 573,310 |
| Referrals | 7,435 | 94,470 |
| Patients with a contact | 16,745 | 183,535 |
Community services (residents of Bury), Jun 2026 (provisional). In June 2026, provisional community services data showed 43.7% of contacts for Bury borough residents were with adults aged 65 and over (25,735 of 58,875 total contacts). High community service contact among older residents highlights an important touchpoint for supportive and palliative care.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF overall achievement ranged from 44.6% at Greyland Medical Centre to 98.0% at Whittaker Lane Med Centre; St Gabriel's Medical Centre achieved 92.5%, matching the England average of 92.5%. Vaccination and immunisation achievement showed a 66.7 pp spread, from 15.6% at Greyland Medical Centre to 82.3% at Whittaker Lane Med Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Birches | 133 | 10.9 | 79.4% | 72.2% | 89.7% |
| Greyland | 85 | 0.0 | 90.1% | 66.3% | 76.9% |
| Fairfax | 125 | 8.2 | 52.0% | 82.6% | 73.4% |
| St Gabriel's | 110 | 29.0 | 60.4% | 47.7% | 68.3% |
| Longfield Medical | 100 | 11.2 | 35.9% | 62.9% | 67.1% |
| Whittaker Lane | 105 | 6.3 | 27.9% | 61.0% | 58.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nine measures trail England over three years despite severe mental illness gains
Over 2023 to 2025, 9 measures trail England's three-year change, led by heart failure reviews, which fell 5.0% to 78.0% while England rose +8.7% to 78.5% (Bury (LAD) +1.4%, NHS Greater Manchester Integrated Care Board +2.1%), and COPD reviews, which fell 3.2% to 73.1% (England rose +2.8% to 76.4%). Conversely, the PCN achieved strong three-year gains in severe mental illness physical health checks: BMI recording rose +12.2 pp to 82.4% (England +5.1 pp), alcohol recording rose +11.9 pp to 84.9% (England +5.4 pp), and blood pressure checks rose +10.7 pp to 83.4% (England +4.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
COPD register
Learning disability register
Stroke register
BMI record (SMI)
Alcohol record (psychosis)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bury (LAD) | Asset | PCN | Bury (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (773 beds) | n/a | Schools (catchment) | 75 | n/a |
| Children's centres | 3 | 8 | Places of worship | 54 | 107 |
| Libraries | 3 | 12 | Primary schools (LA maintained) | 7 | 25 |
| Primary academies | 10 | 33 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and record audit
Hypertension QOF prevalence is 13.0% (5,360 patients) vs 15.2% in Bury (LAD) and 15.2% in England: a crude gap of +794 to +820 patients. For discussion: run an electronic search for patients with repeated raised blood pressure readings without a hypertension code, alongside opportunistic checks at Core20 practices. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
COPD review recall and register validation
COPD prevalence is 1.4% (565 patients vs 2.1% in Bury (LAD) and 1.9% in England; +204 to +267 gap), while reviews fell 3.2% to 73.1%. For discussion: establish structured annual review recall for existing COPD patients and audit records of smokers with repeated respiratory prescribing lacking a diagnostic code. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Heart failure review and register audit
Heart failure prevalence is 0.9% (381 patients vs 1.2% in Bury (LAD) and 1.1% in England; +65 to +110 gap); reviews fell 5.0% to 78.0%. For discussion: audit hospital discharge summaries for uncoded heart failure and standardise annual review templates so functional capacity assessments are consistently captured. Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach strategy (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness check maintenance (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension electronic record audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation catch-up recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening equity outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Hypertension case-finding and record audit (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · COPD review recall and register validation (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Heart failure review and register audit (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
